Now, more than half a year later, the expansion plan for one of the company’s new facilities—a former magazine plant in ...

Following the FDA’s September announcement of a crackdown on direct-to | Monday, the FDA’s Office of Prescription Drug ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by ...

Only days after revealing an unsolicited buyout bid from Lundbeck, Avadel—which has already signed an agreement to sell itself to Alkermes—has officially determined that the Lundbeck offer is sweet | ...

The phase 2 Cadence trial met its primary endpoint, showing that Winrevair improved the ability of blood to transition through the lungs to the heart in patients with combined post- and precapillary ...

Having found swift success with its Jazz Pharmaceuticals and BeOne Medicines-licensed cancer med Ziihera, Zymeworks has ...

Novo revealed Monday that the self-pay cost for the two lowest dosages of Wegovy and Ozempic will be $349 per month, down ...

The clock is up on Biogen’s extra two years of a biosimilar-free U.S. market for its blockbuster multiple sclerosis (MS) med ...

Three years after striking up a Zymeworks licensing pact with an eye on challenging the status quo in HER2-positive cancers, ...

Despite many overseas drugmakers gaining some tariff clarity when the U.S. | Thanks to a new accord with the United States, ...

Cytokinetics is following in the footsteps of Bristol Myers Squibb as it prepares to try to wrest control of a heart disease ...

In the past, biosimilar makers have been able to invalidate some of those patents through a sped-up process called “inter ...